159 results about "Cancer gene" patented technology

The invention discloses an application of a group of gastric cancer related genes. According to the invention, prediction scores are calculated to assess clinical prognosis of gastric cancers and related applications of the clinical prognosis of the gastric cancers based on a group of 53 prognostic related genes in the gastric cancers and a detection result of the expression level of the related genes in a clinical sample. The system can be used for helping gastric cancer patients in therapeutic choices of and prediction of responses to therapeutic intervention to judge whether the patients benefit from chemical and targeted therapies or not, so as to avoid excessive use of drugs and lower medical costs, and finally reach the purposes of precision or personalized medicine. According to the system and different detection technology platforms, corresponding kits for measuring expression of the 53 genes are designed and developed.

The present invention addresses the problem of providing malignant stem cells that can be grown in vitro and are useful in cancer therapy research and drug discovery research for cancer therapy, a method for producing same, cancer cells induced from the cells, and use for the cells. Provided are induced malignant stem cells that can be grown in vitro, the induced malignant stem cells being characterized in (1) having at least one type of abnormality selected from among (a) abnormal methylation (hypermethylation or hypomethylation) of a cancer suppressor gene or cancer-related gene region in the endogenous genome DNA, (b) somatic mutation of a cancer suppressor gene in the endogenous genome DNA or somatic mutation of an endogenous cancer-related gene, (c) abnormal expression (increased expression or decreased / lost expression); of an endogenous cancer gene or endogenous cancer suppressor gene, (d) abnormal expression (increased expression or decreased / lost expression) of non-coding RNA such as endogenous cancer-related micro RNA, (e) abnormal expression (increased expression or decreased / lost expression) of an endogenous cancer-related protein, (f) endogenous cancer-related metabolism abnormality (hypermetabolism or hypometabolism), or (g) abnormal endogenous cancer-related carbohydrate; and (2) expressing the POU5F1 gene, NANOG gene, SOX2 gene, and ZFP42 gene.

Mutant epitopes encoded by cancer genes are virtually always located in the interior of cells, making them invisible to conventional antibodies. We generated single chain variable fragments (scFvs) specific for mutant peptides presented on the cell surface by human leukocyte antigen (HLA) molecules. These scFvs can be converted to full-length antibodies, termed MANAbodies, targeting "Mutation Associated Neo-Antigens" bound to HLA. A phage display library representing a highly diverse array of single-chain variable fragment sequences was first designed and constructed. A competitive selection protocol was then used to identify clones specific for peptides bound to pre-defined HLA types. In this way, we obtained scFvs, including one specific for a peptide encoded by a common KRAS mutant andanother by a common EGFR mutant. Molecules targeting MANA can be developed that specifically react with mutant peptide-HLA complexes even when these peptides differ by only one amino acid from the normal, wild-type form.